Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Plus Therapeutics ( (PSTV) ) is now available.
On August 7, 2025, Plus Therapeutics held its Annual Meeting of Stockholders where five key proposals were voted on. The stockholders elected directors to the board, approved the potential issuance of up to $51 million in common stock to Lincoln Park Capital Fund, and granted the board authority for a reverse stock split. Additionally, the compensation of named executive officers and amendments to the 2020 Stock Incentive Plan were approved. These decisions reflect strategic moves to strengthen the company’s financial position and operational flexibility.
The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.
Plus Therapeutics faces substantial financial and compliance challenges, reflected in its low financial performance and valuation scores. Short-term technical indicators show some positive momentum, but overbought conditions and compliance risks present significant downside potential.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Plus Therapeutics, Inc. operates in the biotechnology sector, focusing on the development of innovative treatments for cancer and other serious diseases. The company is dedicated to advancing its proprietary nanotechnology platform to enhance the delivery and efficacy of therapeutic compounds.
Average Trading Volume: 31,164,649
Technical Sentiment Signal: Sell
Current Market Cap: $42.34M
For a thorough assessment of PSTV stock, go to TipRanks’ Stock Analysis page.